AVIR Atea Pharmaceuticals, Inc.

Atea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases.

$40.65  +1.37 (3.49%)
As of 10/18/2021 15:59:56 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  10/30/2020
Outstanding shares:  82,776,937
Average volume:  3,154,696
Market cap:   $3,348,327,102
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    04683R106
ISIN:        US04683R1068
Valuation   (See tab for details)
PE ratio:   61.46
PB ratio:   5.44
PS ratio:   19.13
Return on equity:   5.90%
Net income %:   20.16%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy